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Abstract: In continuation of our interest in identifying new α-glucosidase inhibitors with potential to become antidiabetic drugs, this
work focuses on the study of 4-(dimethylaminoalkyl)piperazine-1-carbodithioate derivatives as α-glucosidase inhibitors. The eight
heterocyclic piperazine-dithiocarbamate complexes studied in this work contain a variety of substitutions on their benzene ring
exhibiting potent, noncompetitive inhibition of α-glucosidase. Dithiocarbamate and piperazine moieties are important pharmacophores
with promising therapeutic prospects featuring facilitated drug delivery due to their lipophilic nature in addition to their α-glucosidase
inhibitory activity. Enzyme kinetics, molecular dynamics simulations, and docking studies revealed that the target compounds bind to
a new allosteric site that is located near the active site of α-glucosidase. Majority of molecular interactions of the compounds with the
enzyme are mediated by hydrophobic contacts in addition to a number of important polar interactions. The current work identifies a
number of chemical groups in the compounds that are responsible for potent inhibition of α-glucosidase. Moreover, it also provides new
insights into understanding α-glucosidase inhibition by dithiocarbamate and piperazine-containing compounds that can be promising
for development of new antidiabetic drugs.
Key words: Alpha-glucosidase inhibitor, dithiocarbamate, piperazine, noncompetitive, allosteric

1. Introduction
Intestinal α-glucosidases are a class of enzymes that are essential for digestion of dietary carbohydrates [1]. One of the
treatment approaches for controlling hyperglycemia manifested in diabetes mellitus is inhibition of α-glucosidase [2].
The current therapeutic regime for treatment of diabetes includes only a limited number of oral α-glucosidase inhibitors
namely acarbose, miglitol, and voglibose. Their low efficacy and gastrointestinal side effects are major obstacles to achieving
promising therapeutic outcome. Unfortunately, no significant progress has been made in the drug development of oral
α-glucosidase inhibitors. Therefore, this area needs attention to develop new α-glucosidase inhibitors with better efficacy,
less side effects, and more therapeutic benefits [3-4].
Carbamate and piperazine moieties have been shown to exhibit promising biological activities for treatment of
Alzheimer’s disease and a number of other central nervous system (CNS) disorders [5]. Dithiocarbamate, an isostere
of carbamate, is a promising pharmacophore in the drug development of CNS-related disorders especially for drug
delivery due to its lipophilic properties [6]. Moreover, the piperazine moiety exhibits diverse biological activities such as
antiparasitic, antimicrobial, antipsychotic, antidepressant, and anxiolytic activities [7]. Furthermore, compounds bearing
the piperazine moiety are also known to possess potent inhibitory activity against α-glucosidase including chiral piperazine
diones [8], 2-furoic piperazides [9], triazole-containing piperazines [10], and phenylpiperazines [11]. Presently, there are
a very limited number of reports on dithiocarbamates as inhibitors of α-glucosidase that include coumarin-containing
dithiocarbamates [12], and benzyl carbamates [13]. Nevertheless, these derivatives are a promising class of emerging
compounds that exhibit potent inhibition of α-glucosidase. Our recent work on dithiocarbamates α-glucosidase inhibitors
* Correspondence: ughani@gmx.net
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targeted benzylamine and piperazine derivatives [14]. This work focuses on a series of novel 4-(dimethylaminoalkyl)
piperazine-1-carbodithioate derivatives with various substitutions on their benzene ring exhibiting potent inhibition of
α-glucosidase. The current work will not only provide new avenues to study the effects of the substitutions on the benzene
ring but will also incorporate chemical diversity to dithiocarbamate inhibitors of α-glucosidase.
In this work, eight piperazine-containing carbodithioate derivatives containing various substitutions on their benzene
ring (PC1-PC8) have been newly identified as noncompetitive inhibitors of α-glucosidase with focus on kinetics and
computational studies. Docking and molecular dynamics (MD) simulations revealed important clues to understanding
their interactions with the enzyme at molecular level. The work also identifies a new allosteric site on the enzyme to
which the target compounds bind and influence its catalytic activity. Both dithiocarbamate and piperazine moieties along
with the substitutions actively contribute to enzyme inhibition. MD simulations showed that the compounds bind to an
allosteric site that is located near the active site revealing a number of important interactions with its amino acid residues.
The current findings incorporate chemical diversity that would be valuable to understanding α-glucosidase inhibition by
dithiocarbamate derivatives, and for searching new and effective α-glucosidase inhibitors as antidiabetic drugs.
2. Materials and methods
2.1. Synthesis and structure elucidation of the compounds
The design, synthesis, and structure elucidation of all target compounds studied in this work have been previously reported
[15].
2.2. α-Glucosidase inhibition assay
All in vitro α-glucosidase inhibition assays were performed in a 96-well microplate format. The α-glucosidase inhibition
assay reported elsewhere was customized to suit the experimental needs of the current work [16]. The assay mixture
contained 50 mM sodium phosphate buffer (pH 6.8), 20 mU of α-glucosidase (EC 3.2.1.20) from Saccharomyces cerevisiae
(Sigma Chemical Co., St. Louis, USA), and 1.0 mM of p-nitrophenyl-α-D-glucopyranoside (PNP-G) substrate. All
target compounds were dissolved in DMSO with the assay mixture containing DMSO at a final concentration of 3%.
All compounds were first incubated with the enzyme at 37 °C for 15 min followed by commencement of the enzyme
reaction by adding the substrate. The reaction was continuously monitored at 400 nm in SpectraMax Plus 384® microplate
reader (Molecular Devices, CA, USA). The assay also included separate, parallel sets of control experiments containing no
compounds as negative control, and acarbose as positive control. All assays were performed as four individual experiments
out of which the values of mean and standard error of mean (SEM) were calculated.
2.3. α-Glucosidase inhibition kinetics
The enzyme kinetics assay procedure was essentially the same as mentioned above except that it was specifically designed
for the kinetic work. The experiments included the addition of a range of target compound concentrations and that of
the substrate (0.25–2.0 mM). In all experiments, only the linear portion of the enzyme reaction curves was selected for
calculating initial velocities in the presence and absence of the target compounds. The type of inhibition was calculated
from the Lineweaver-Burk plots which was further confirmed by the Dixon plot using Grafit 7.0.3 software (Erithacus
Software Ltd., Staines, UK). The Ki values were also calculated from their respective Dixon plots. All kinetic experiments
were conducted in quadruplicate from which mean Ki values and the SEM were calculated.
2.4. Computational studies
2.4.1. α-glucosidase homology model building
The target compounds were docked into the homology model of S. cerevisiae α-glucosidase that we built and reported in
our previous work [14].
2.4.2. Docking and MD simulations
The chemical structures of the target compounds were drawn in the builder module in MOE-2015.1001 followed by
addition of charges and energy minimization in MMFF94x force field [17]. A conformation search run was conducted
in MOE to determine conformation with lowest energy which was selected for further studies. The default induced-fit
docking protocol (triangle matcher) was chosen to perform molecular docking of the compounds that deployed two
scoring functions namely London dG and GBVI/WSA dG. The protocol generated 30 poses for each compound followed
by visual analysis of the top-ranked pose for each one.
In order to determine the conformational changes and stability of the predicted enzyme-ligand complexes, the docking
poses were further analyzed by MD simulation. The AMBER18 suite was utilized for a production run of 50 ns simulation
[18] for which all systems were prepared using the LEaP module in AMBER18. Application of parameters to the compounds
and the enzyme was performed using AMBER force field (GAFF) and AMBERFF14SB, respectively. Assignment of the
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AM1-BCC charges to the ligands was carried out in the ANTECHAMBER program. Solvation of all systems was conducted
using the cubic TIP3P water box leaving a margin of 10 Å under the periodic boundary conditions [19]. The systems were
neutralized by replacing water molecules with appropriate counter ions. Initially, the energy minimization of each system
was performed to remove the steric clashes between protein-ligand and protein-solvent molecules using the steepest
descent procedure followed by conjugated gradient. Gradual heating was performed by raising the temperature from 0 K
to 300 K for a time period of 500 ps. Each system was then equilibrated under the NPT ensemble for another 500 ps at a
constant temperature (300 K) and pressure (P = 1 atm) with a coupling constant of 1.0 ps [20]. The SHAKE algorithm was
utilized to constrain all hydrogen and other bonds [21]. The long-range electrostatic interactions were calculated using
the particle mesh Ewald method with a distance cutoff of 8 Å [22]. A final production run of 50 ns for all systems was
performed using the PMEMD.CUDA from AMBEER18 with an integration time of 2 fs that turned out trajectories which
were analyzed in the CPPTRAJ module [23] of AMBER18.
2.4.3. MM-PBSA / GBSA calculations
Calculation of free energy of binding is one of the promising approaches to computing ligand-protein binding affinities.
For the current work, it was conducted by molecular mechanics-Poisson-Boltzmann surface area/generalized Born surface
area (MM-PBSA / GBSA) method based on 1000 frames extracted from the equilibrated trajectories of all three systems.
The ΔGBinding between a ligand and a receptor to form a complex were calculated by using the following equation:
ΔGBinding = GComplex − (Glig+Grec)
= ΔEMM + ΔGGB + ΔGSA − TΔS
= ΔEvdw + ΔEele + ΔGGB + ΔGSA – TΔS,
where the term ΔEMM depicts the energy of gas-phase interaction between ligand and protein complex comprising the
electrostatic energy contribution (ΔEele) and van der Waals energy contribution (ΔEvdw). The ΔGG and ΔGSA represent the
polar and nonpolar components of desolvation free energies, respectively. In this work, the ΔGSA and ΔGGB were estimated
using the accessible surface area (SASA) model with the LCPO method: ΔGSA = 0.0072 × ΔSASA and generalized Born
(GB) model, respectively.
3. Results and discussion
3.1. α-Glucosidase inhibition kinetics
Compared to negative controls containing no inhibitors, a concentration-dependent decrease in the α-glucosidase reaction
rate was observed in the presence of the target compounds. The Ki values of the compounds ranged from 5.75 to 29.36
µM as listed in Table 1. Analysis of the raw kinetic data from each experiment, with least standard of error, was conducted
for determining the type of inhibition exhibited by each compound using the reciprocal transformation of the MichaelisMenten equation. Lineweaver-Burk plots were used to screen the data for best fit into a potential type of inhibition [24].
Calculation of Vmaxapp and Kmapp values matching with the type of inhibition was also performed. Lineweaver–Burk plots
defining the type of inhibition for each compound with least standard of error were considered for further analysis. All
target compounds demonstrated noncompetitive inhibition of α-glucosidase as shown by their respective Lineweaver–
Burk plots. Dixon plots {1/v versus [I]} [25] were utilized to determine the Ki values for all compounds by rearranging the
Michaelis-Menten equation. The Dixon and Lineweaver–Burk plots for representative inhibitors are presented in Figure 1.
3.2. Structure-activity relationship
The target compounds possess substitutions on the phenyl ring adjacent to the oxoethyl group with varying number of alkyl
carbon atoms connecting the piperazine-1-carbodithioate moiety. PC1 (Ki = 5.75 µM) bearing a 4-chlorophenyl substitution,
demonstrated most potent inhibition of α-glucosidase. PC2 (Ki = 12.70 µM), derivatized by a 2,4-dichlorophenyl group,
showed 2-fold less activity than PC1. In addition to these substitutions in PC1 and PC2, the differences in their potency
also appear to be due to the oxobutyl and oxoethyl groups, respectively. PC1 is extended by one more carbon atom, which is
apparently an important feature contributing to more potent inhibition of the enzyme than by PC2. This feature is also present
in PC6 (Ki = 20.93 µM); however, its phenyl ring is unsubstituted, exhibiting much less potency when compared to PC1,
emphasizing the importance of the phenyl ring substitutions for potent inhibition of the enzyme. The chlorine-containing
compounds (PC1 and PC2) were identified as relatively more potent inhibitors than the ones bearing other groups. The Ki
values of the rest of the compounds, carrying fluorine, bromine and hydroxyl groups, were found to be similar to each other.
PC3, PC4, and PC5 exhibited similar inhibitory activities despite having differences in the position of their substituent
groups. All of these compounds bear a 4-fluorophenyl substitution except for PC3 which bears an additional fluorine
atom at the 2-position of the phenyl ring (2,4-difluorophenyl substitution). Moreover, PC4 is slightly extended due to its
oxopropyl group compared to PC3 and PC5 that carry an oxoethyl group. All these differences in the types and positions
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Table 1. The structures and Ki values of the target inhibitors, all of
which noncompetitively inhibited α-glucosidase. The Ki values are the
mean of quadruplet experiments with SEM.
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Figure 1. Representative Dixon (a,c) and Lineweaver–Burk plots (b,d)
exhibiting noncompetitive inhibition by the compounds.
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of the substituent groups did not affect the activities of these compounds. It is interesting to note that bromine is not
optimal for enzyme inhibition; PC8 bearing 4-bromophenyl and oxoethyl groups showed least activity (Ki = 29.36 µM).
It is clear from the above data that chlorine substantially contributes to potent inhibition of α-glucosidase. However,
comparison of other halogen-containing compounds (PC3, PC4, PC5 and PC8) with the ones devoid of halogens such as
PC6 and PC7 (bearing hydroxyl groups) revealed no major differences in their activities. PC9 possessing an unsubstituted
phenyl ring and an oxopropyl group showed no inhibitory activity, which is very similar to PC6 carrying an oxobutyl
group but with one more carbon atom connecting the two moieties. Interestingly, a single carbon atom makes a striking
difference between these two compounds rendering one to be inactive. This is consistent with the results discussed above
showing that oxobutyl moiety partly contributes to potent α-glucosidase inhibition in addition to phenyl substitutions.
Moreover, the additional carbon atom in PC6 extends the molecule that appears to facilitate access to enzyme residues for
a better interaction.
3.3. Computational studies
As mentioned earlier, all target compounds noncompetitively inhibited α-glucosidase which infers that they bind to a site
on the enzyme other than the active site. This is consistent with the previous studies by Proenca et al. [26] who reported that
the larger size of the binding cavity of α-glucosidase is primarily responsible for a range of inhibitor binding modes leading
to various types of enzyme inhibition. In order to cater to search for a potential binding site, blind docking protocols
were followed for the compounds along with their binding modes. The docking results identified a new allosteric site
that is located in the close proximity of the active site. The site is primarily composed of Lys152, Ser153, Phe154, His236,
Asn238, Val300, Glu301, Gly303, Pro306, Phe307, Arg309, and Arg353 residues. A cluster of compounds with various
conformations was found at this site where the compounds specifically interact with Lys152, Phe154, Val300, Pro306,
Phe307, and Arg309 residues. The target compounds (PC1, PC2, and PC5) selected for docking and MD simulations bind
to this region of the enzyme where their molecular interactions take place with various residues mentioned above. The
docking scores for the compounds are listed in Table 2.
We compared our newly-identified allosteric site with known ones reported in the literature for yeast α-glucosidase
[27-29], and with the one identified in our previous work [14]. Majority of the reported sites are located in the vicinity of
each other as revealed by their amino acid sequence. Comparison of their sequence with that of our site indicated that it
is located in the close proximity to at least three of the known sites [27-28] including that of our previously identified site
[14]. This shows that the site is part of a large enzyme region where those known sites are generally located. Despite this
close proximity, our site is formed of amino acid residues that are different from that of the known ones; hence, the site is
new which is constituted by unique amino acid residues.
Since the target compounds are noncompetitive inhibitors of α-glucosidase, they apparently regulate substrate
binding through the allosteric site. We have previously shown that all known allosteric sites are located in close proximity
to the active site [14] that appears to directly influence the binding of the substrate (PNP-G) by apparently inducing
conformational changes in the active site pocket resulting in enzyme inhibition. Study of the exact mechanism of the
conformational changes warrants separate future investigations involving dedicated and exhaustive computational work.
Since molecular docking only depicted a static picture of the molecular interactions of the ligands with the enzyme, we
further expanded our work by performing MD simulation experiments that highlighted various system properties with
respect to time that were difficult to attain otherwise.
3.4. Structural stability analysis
Root mean square deviation (RMSD) plays a crucial role in describing the system stability during MD simulations. Initially,
the stability and deviation of each complex was investigated in order to calculate the positional differences of backbone
atoms from its initial structure. RMSD calculations (Figure 2) revealed that the assembly was not fully equilibrated until 10
ns into the production run (as determined by the protein RMSD); therefore, only the remaining 40 ns were considered for
subsequent calculations. As evident from Figure 2, all systems displayed variable deviations with an average RMSD value
of 2.5–3.2 Å with stable internal motion.
Root mean square fluctuation (RMSF) analysis was performed to investigate the flexibility of α-glucosidase residues.
The results over the time scale for all three systems are presented in Figure 3. A large fluctuation in residues 229, 278, and
400–435 was observed for all three enzyme-inhibitor complexes. Visual assessment of these residues interpreted by the
secondary structure suggested that these residues are part of the loops which are highly flexible in nature. Apart from this
fluctuation, other sites were calculated to be comparatively stable. Analysis of the MD trajectories revealed that all the
target compounds (PC1, PC2, and PC5) presented significant dislocation in the coordinates before and after simulation,
exhibiting differences of 2.06, 2.48, and 2.54 Å, respectively. However, the interactions were later stabilized by hydrophobic
interactions displayed by the compounds.
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Figure 2. Root mean square deviation (RMSD) as a function
of time for the protein backbone. A production run of 50 ns
revealed that all systems demonstrated variable deviations with
an average RMSD value of 2.5–3.2 Å with stable internal motion.

Figure 3. Root mean square fluctuation (RMSF) as a function of
time for the protein backbone.

Table 2. Docking scores for PC1, PC2, and PC5.
Inhibitor

Docking scores

PC1

–7.2339

PC2

–7.9760

PC5

–8.2346

PNP-G

–7.0442

3.5. Molecular interactions
Time-dependent analysis of PC1 bound to the enzyme revealed that its carbonyl group is involved in hydrogen bonding
interaction with the side chain of Arg309 at a distance of 2.09 Å. The complex is further stabilized by the halogen bonds
between the Cl at para position and Arg353, and Gln347 residues through chlorine. The carbodithioate moiety of PC1
is involved in π-sulfur interactions with His236, whereas the aliphatic chain of its dimethylaminopropyl group forms
hydrophobic contacts with Asn238 and Phe154 residues (Figure 4a). Its piperazine moiety extends and stabilizes the
attached aliphatic chain that is aligned between the Asn238 and Phe154 residues. Detailed interaction profiles of selected
target compounds with important residues of the binding site are provided in Table 3.
The carbonyl group of PC2 (Figure 4b) is involved in hydrophilic interactions with the side chain of Asn238 at a distance
of 3.14 Å. Its carbodithioate moiety is stabilized by His276 residue through hydrophobic interactions. The carbonyl group
of PC5 is stabilized by hydrophilic interactions with the side chain of Ser153 at a distance of 2.56 Å (Figure 4c), while its
carbodithioate moiety forms hydrophobic contacts with Phe154 and Arg309 residues. The dichlorobenzene ring of PC2
and the fluorobenzene ring of PC5 are involved in parallel π-stacking interactions with Phe154 residue. Additionally, PC2
is involved in hydrogen bonding interaction with Gly303 whereas PC5 is further stabilized by a salt bridge between its
tertamine and the carboxylate group of Glu301 residue. These interactions exhibited by both compounds could not have
been possible without assistance from the piperazine ring and the aliphatic chain that extend the molecule thus enabling
their access to respective residues. The results indicate that hydrophobic interactions have a key influence on enzymeinhibitor binding as expected due to the lipophilic characteristics of the compounds. However, there is also a significant
role of the carbonyl groups of the compounds in enzyme inhibition that establish polar contacts with the residues located
in the allosteric site.

1489

GHANI et al. / Turk J Chem
3.6. Analysis of free energy of binding
The MM-PBSA/GBSA free energy calculations were utilized to obtain insights into the forces involved in the enzymeinhibitor binding. To determine the binding affinities of all three systems, 1000 frames were extracted from the last 5 ns
of the MD production. The calculated binding energy for PC1, PC2, and PC5 were –37.0360, –38.5350, and –35.3002,
respectively. In order to comprehend the influence of specific energy terms in the binding process, the total free energy
was disintegrated into Eele, Evdw, ESURF, and EGB energy components. The results presented in Table 4 suggested that
the intermolecular van der Waals interactions (ΔEint vdW) contribute more significantly to the binding free energies than
electrostatic interactions (ΔGele), which is consistent with the MD results and with the chemical nature of the compounds.
The nonpolar solvation terms, corresponding to burial SASA upon inhibitor binding, favorably contributed to the binding
affinity to some extent. However, the total binding affinity appears to be due to a more complex interplay between all these
components.

Figure 4. Binding modes of (a) PC1, (b) PC2, and (c) PC5. The enzyme residues are drawn as thick white sticks, and the dashed red lines
represent hydrogen bonding interactions. For clarity purposes, residues only interacting with the inhibitors are shown.

Table 3. The ligand–protein interaction profiles of selected inhibitors within the α-glucosidase binding site (abbreviations: MD =
molecular dynamics; Lig. = ligand).

Inhibitor

van der Waals Interactions post-MD

PC1

Hydrogen bond and salt bridge interactions post-MD
Acceptor atom

Donor atom

Distance Å

Ser153, Phe154, Val300, Phe307, Glu301, Arg353

Lig: Carbonyl=O9
Lig: Cl

Arg309-NH1
Arg353-NH1

2.9 ± 0.36
3.34 ± 0.52

PC2

Lys152, Ser153, Phe154, Glu301, Pro306, Phe307

Lig: Carbonyl=O
Lig: N2

Asn238-NH2
Gly303-NH1

2.04 ± 0.44
2.3 ± 0.62

PC5

Lys152, Ser153, Phe154, Glu301, Phe307, Arg309

Lig:
N2

Glu301-OE

3.9 ± 0.58

Table 4. Contribution of each energy component to the binding of all three simulated systems (kcal/mol).
System

Evdw

Eele

EGB

ESURF

ΔGbinding (GB)

PC1

–44.5426

–20.0809

30.4908

–4.4710

–38.0360 ± 2.2

PC2

–46.3578

–18.4149

31.7248

–5.4826

–36.5350 ± 2.0

PC5

–49.8309

–18.0814

38.2362

–5.6240

–35.3002 ± 2.4
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4. Conclusion
The novel 4-(dimethylaminoalkyl)piperazine-1-carbodithioate derivatives studied in this work demonstrate
noncompetitive inhibition of yeast α-glucosidase. The compounds feature various halogen substitutions along with the
oxoalkyl groups of different carbon lengths that exerted cumulative effect on enzyme inhibition. The results showed
that the halogen substitutions on the benzene ring and the length of the oxoalkyl groups were crucial for α-glucosidase
inhibition. Additionally, the docking and MD studies have helped to identify a new allosteric site on the enzyme to
which the target compounds bind and apparently influence the catalytic activity. Computational studies have predicted
interactions of the target compounds with the enzyme at molecular level that is predominantly governed by hydrophobic
and to some degree by electrostatic interactions. The piperazine moiety allows extension of the aliphatic chain and the
dimethylaminopropyl group for access to the region of the allosteric site where they form hydrophobic and polar contacts
with the residues, respectively. The current work reveals clues to understanding α-glucosidase inhibition by piperazinecontaining dithiocarbamate derivatives at molecular level that will be useful for new antidiabetic drug discovery.
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